Just saw AbbVie filed for FDA approval on Rinvoq for treating vitiligo - kind of a big deal if you follow biotech. They've been testing this for non-segmental vitiligo specifically, and apparently the Phase 3 data looked solid with patients showing major skin repigmentation improvements by week 48. The thing about vitiligo is it's been tough to treat, so a new option could actually matter for patients dealing with it. Rinvoq is already approved for stuff like rheumatoid arthritis and Crohn's, so they're basically expanding the drug into dermatology now. If the FDA and EMA greenlight this vitiligo indication, could open up a whole new market for them. Curious to see how long the approval process takes - these things usually move pretty slow. Anyone tracking AbbVie's pipeline?

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin